AAN2024 Ocrelizumab Ocrelizumab 10 years on 10 years of anti-CD20 and it looks good for 75% of people in not developing progression over 48 weeks and this was about 20% better if you started treatment earlier rather than later Hauser et al. 10 Years of Ocrelizumab Treatment in Multiple Sclerosis: Long-term Efficacy and Safety Clinical Trial Data […]
https://multiple-sclerosis-res....earch.org/2024/04/aa